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The systemic injection of -hydroxybutyric acid (GHB) elicits spike and wave discharges (SWDs), the EEG hallmark of absence seizures,
and represents a well established, widely used pharmacological model of this nonconvulsive epilepsy. Despite this experimental use of
GHB, as well as its therapeutic use in narcolepsy and its increasing abuse, however, the precise cellular mechanisms underlying the
different pharmacological actions of this drug are still unclear.
Because sensory thalamic nuclei play a key role in the generation of SWDs and sleep rhythms, and because direct injection of GHB in
the ventrobasal (VB) thalamus elicits SWDs, we investigated GHB effects on corticothalamic EPSCs and GABAergic IPSCs in VB thalamo-
cortical (TC) neurons. GHB (250 M–10 mM) reversibly decreased the amplitude of electrically evoked EPSCs and GABAA IPSCs via
activation of GABAB receptors; however,60% of the IPSCs were insensitive to low (250M-1.0 mM) GHB concentrations. The putative
GHB receptor antagonist NSC 382 applied alone had a number of unspecific effects, whereas it either had no action on, or further
increased, the GHB-elicited effects on synaptic currents. Low GHB concentrations (250M) were also effective in increasing absence-like
intrathalamic oscillations evoked by cortical afferent stimulation.
These results indicate that low concentrations of GHB, similar to the brain concentrations that evoke SWDs in vivo, differentially affect
excitatory and inhibitory synaptic currents in TC neurons and promote absence-like intrathalamic oscillations. Furthermore, the present
data strengthen previous suggestions on the GHB mechanism of sleep promotion and will help focus future studies on the cellular
mechanisms underlying its abuse.
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Introduction
Administration of -hydroxybutyric acid (GHB) elicits euphoric
sensations, sedation, normalization of sleep parameters, and
spike and wave discharges (SWDs), the EEG hallmark of absence
seizures (Tunnicliff and Cash, 2002). Some GHB effects are clin-
ically exploited (i.e., in anesthesia, alcohol withdrawal, and nar-
colepsy) (Lammers et al., 1993; Kleinschmidt et al., 1998; Pol-
drugo and Addolorato, 1999), whereas others underlie its illicit
use as a recreational and so-called “rape” drug (Boyce et al., 2000;
Nicholson and Balster, 2001). Experimentally, GHB-elicited
SWDs are a well established model of absence seizures (Snead,
1995) that are used to assess the effect of pharmacological–trans-
genic manipulations of neuronal channels and receptors on the
expression of this paroxysmal activity (Snead et al., 2000; Kim et
al., 2001).
The mechanisms of GHB actions, however, are unclear. The
existence of (1) binding sites with a specific brain distribution
[different from those of GABAA receptors (GABAARs) and
GABAB Rs] (Bernasconi et al., 1999), (2) high-affinity ligands
(that do not displace GABA or baclofen from GABAA and GABAB
sites) (Maitre et al., 1990), and (3) biochemical and behavioral
responses that are blocked by NCS 382 (the only available GHB
antagonist) (Maitre et al., 1990; Schmidt et al., 1991; Hechler et
al., 1993; Snead, 1996; Ferraro et al., 2001; Mehta et al., 2001) has
led to the proposition that there are physiologically relevant brain
GHB receptors (Maitre, 1997). In contrast, other biochemical
and behavioral data indicate that GHB only acts as a weak GABAB
receptor agonist (Bernasconi et al., 1999), and isolation of GHB
receptor(s) has been elusive (Cash and Tunnicliff, 2002).
Electrophysiological results are also contradictory (Crunelli and
Leresche, 2002b), because in vivo studies show GHB responses that
are mediated by putative GHB receptors, whereas most of the in vitro
investigations highlight GABAB receptor-mediated responses, a re-
sult confirmed by data from recombinant GABAB receptors (Lin-
genhoehl et al., 1999). The only exception to this scenario is the
GHB-mediated modulation of Ca2 currents in NCB20 cells, which
is NCS 382 sensitive (Kemmel et al., 2003).
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Sensory thalamic nuclei play a key role in SWDs (Crunelli and
Leresche, 2002a) and sleep rhythms (Steriade et al., 1997). Taking
advantage of current knowledge of thalamic GABAB (Emri et al.,
1996a; Ulrich and Huguenard, 1996; Kim et al., 1997; Le Feuvre et
al., 1997) and putative GHB receptors (Hechler et al., 1992), and
because GHB injection in the ventrobasal (VB) thalamus elicits
SWDs (Snead, 1991), we investigated in VB thalamocortical (TC)
neurons whether, and via which receptors, GHB affects cortico-
thalamic EPSCs and GABAAergic IPSCs originating from the nu-
cleus reticularis thalami (NRT). We report that GHB elicits a
GABAB-mediated reduction of EPSCs and IPSCs, but only 41%
of the IPSCs are sensitive to concentrations 1 mM. Low GHB
concentrations also increase slow intrathalamic oscillations
evoked by cortical stimulation. These results indicate that low
GHB concentrations differentially affect excitatory and inhibi-
tory synaptic currents in TC neurons and are discussed in the
context of the ability of similar brain GHB concentrations to
generate SWDs in vivo.
Preliminary data have been published in abstract form (Mon-
nier et al., 2000).
Materials and Methods
Whole-cell recordings. A block containing the thalamus was dissected
from the brain of male 10- to 22-d-old Wistar rats (mean 14  2), and
corticothalamic (400m thick) or horizontal (220m thick) slices con-
taining the NRT and ventral posterolateral and ventral posteromedial
nuclei were prepared in ice-cold saline, as described by Agmon and Con-
nors (1991) and Le Feuvre et al. (1997), respectively, using a Vibroslice
(Leica VT1000S). Slices were kept at 35°C in oxygenated saline (95%
O2/5% CO2), before being transferred, one at the time, to the experimen-
tal setup, where they were maintained at room temperature and perfused
at a rate of 1–2 ml/min with an oxygenated medium of composition (in
mM): 125 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 26 NaHCO3,
and 25 glucose, pH 7.3.
Membrane currents were recorded from the soma of TC neurons vi-
sualized under Nomarski optics. Recording pipettes were pulled from
borosilicate glass using a Narishige (Tokyo, Japan) micropipette puller
and coated with wax. For recording synaptic currents, electrodes were
filled with the following solution (in mM): 115 CsCl, 1 CaCl2, 5 MgCl2, 10
EGTA, 10 HEPES, 4 Na-ATP, 0.4 Na-GTP, 15 phosphocreatine, and 50
U/ml creatine phosphokinase, pH 7.3 (osmolarity, 305 mOsm) (elec-
trode resistance, 1.5–2 M). Once a high-resistance seal had been estab-
lished, the holding potential was set to 60 mV, and the whole-cell,
voltage-clamp configuration was obtained. Values of access resistance
ranged from 4 to 6 M at the beginning of the recording to 4 – 8 M at
the end. At least 70% of these values were compensated. Patch-clamp
electrodes were connected to an Axopatch 200B amplifier (Axon Instru-
ments, Foster City, CA). Voltage protocols and acquisition were con-
trolled by Axograph 4.8. The membrane currents were filtered by a four-
pole Bessel filter set at a corner frequency of 5 kHz, digitalized on-line at
a sampling rate of 10 or 20 kHz, and later analyzed using Axograph 4.8
(Axon Instruments). Data were not collected until 10 min after patch
rupture to allow the internal and external solutions to equilibrate.
Isolation of glutamatergic EPSCs was obtained by adding the GABAer-
gic antagonist, gabazine (1–10 M), to the perfusion medium. Isolation
of GABAA IPSCs was obtained by adding to the perfusion medium the
glutamate antagonists, DL-APV (50 M) and CNQX (10 M) (Eaton and
Salt, 1996; Salt, 2002). Evoked postsynaptic currents were recorded from
a holding potential of 60 mV. Evoked IPSCs were elicited by extra-
cellular electrical stimulation, using an electrode consisting of a glass
pipette (6 – 8 m tip diameter) filled with the extracellular medium, and
a remote 100-m-thick platinum wire. The stimulating electrode was
positioned 25– 60 m from the recorded neuron. Evoked cortico-
thalamic EPSCs were elicited using a bipolar metallic electrode located in
the internal capsula, close to the NRT. Square pulses of 20sec duration
and 10 – 40 V amplitude were applied at a frequency of 0.05 Hz to evoke
EPSCs or IPSCs.
The perforated-patch technique was used to record outward K cur-
rents, because it provided more stable recordings. The patch electrodes
were filled with 1 l of the following solution (in mM): 130 KCl, 10
HEPES, 1 EGTA, 1 MgCl2, 0.1 CaCl2, pH 7.3 (osmolarity, 305 mOsm). A
quartz capillary was loaded with 0.5 l of pipette solution in which 100
M amphotericin B from a fresh stock solution in DMSO and 10 M
fluorescein were added. The 10-m-diameter tip of the capillary was
placed close to the tip of the recording pipette, and the solution was
ejected once the cell-attached configuration had been obtained, leading
to a rapid decrease in the series resistance. The integrity of the membrane
patch was monitored with the fluorescein fluorescence.
Extracellular recordings. Extracellular recordings were performed in
adult rat horizontal slices (prepared as described previously) maintained
at 35°C, using an interface recording chamber and glass pipettes filled
with 0.5 M NaCl (resistance, 1–5 M) connected to a Neurolog 104
amplifier (Digitimer Ltd., Welwyn Garden City, UK). The extracellular
medium contained (in mM): 134 NaCl, 3.75 KCl, 1.25 KH2PO4, 1
MgSO4, 2 CaCl2, 16 NaHCO3, 10 glucose. Multiunit activity was evoked
by delivering a brief electrical stimulus (100 –200 sec; 50 –100 V) to
the internal capsule using a bipolar tungsten electrode. The oscillatory
index was calculated as the ratio of the first satellite peak to the central
peak of the autocorrelogram, expressed as a percentage (Huntsman et al.,
1999).
Quantitative data obtained with both extracellular and patch electrode
recordings are given as mean  SD, and the statistical significance was
tested using Student’s t test.
Drugs. Solutions containing ()baclofen, GHB, NCS 382, NCS 356,
trans-4-hydroxycrotonic acid (4-HCN), CGP 56999A, and CGP 35348
were prepared immediately before the experiment. All drugs were bath
applied. We thank Novartis (Basel, Switzerland) for their gift of CGP
56999A and CGP 35348, and Dr. J. J. Bourguignon (Unite´ Mixte de
Recherche Centre National de la Recherche Scientifique 7081, Stras-
bourg, France) for NCS 356. All other chemicals were purchased from
Sigma and Tocris.
Results
GABAB receptors on corticothalamic afferents
Before assessing the action of GHB on corticothalamic EPSCs, we
investigated the effects of the GABAB receptor agonist baclofen at
this synapse, because no study has so far addressed this issue. As
shown in Figures 1 and 2, electrical stimulation of the corticotha-
lamic afferents evoked in VB TC neurons two types of EPSCs that
differ in their kinetics, with the longer-lasting type of EPSCs be-
ing recorded more frequently, as reported previously by Kao and
Coulter (1997).
Application of ()baclofen dose-dependently and reversibly
decreased the amplitude of corticothalamic EPSCs in all neurons
tested (Fig. 1A,B). The effect of baclofen reached steady-state
between 2 and 3 min from the beginning of the application, and
the recovery was obtained between 10 and 12 min after the start of
the washout. The reduction observed with 0.1, 0.5, 1, 10, and 20
M baclofen was 15 4% (n 7), 47 9 (n 8), 55 6% (n
9), 78 11% (n 14), and 85 6% (n 4), respectively (IC50,
0.48 M) (Fig. 1C). The decreases obtained with 10 and 20 M
baclofen were not statistically different ( p  0.05), suggesting
that 10 M baclofen already provides a maximal activation of the
GABAB receptors present at this synapse. The GABAB receptor
antagonists CGP 35348 (1 mM) (n 3) or CGP 56999A (100 nM)
(n 15) not only fully antagonized the 10 M baclofen-induced
reduction of the EPSC, but also increased the amplitude of the
EPSC above the control level (Fig. 1A,B), as has already been
shown for both the sensory EPSP (Emri et al., 1996a) and the
NRT-derived IPSPs in TC neurons (Le Feuvre et al., 1997). No
difference in baclofen potency and the effect of GABAB antago-
nists was observed between EPSCs with different kinetics.
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Effect of GHB on the corticothalamic EPSC
Having established the action of baclofen, we then investigated
the effect of GHB on electrically evoked corticothalamic EPSCs.
Application of GHB reversibly decreased the amplitude of these
EPSCs in 96% of TC neurons. The effect of GHB reached steady-
state between 2 and 3 min from the beginning of the application,
and the recovery was obtained between 10 and 12 min after the
start of the washout. No effect was observed with 100 M GHB
(n 3), whereas 250 M evoked a reduction (17 3%) in seven
of eight neurons (Fig. 2A). Increasing the GHB concentration to
500M, 1 mM, 10 mM, and 20 mM elicited a decrease of 27 10%
(n 34 of 36), 25 10% (n 6 of 6), 56 11% (n 5 of 5), and
61 13% (n 5 of 5), respectively (Figs. 2B, 4A,B). In the two
neurons in which 500 M GHB was ineffective, subsequent ap-
plication of baclofen markedly decreased the amplitude of the
EPSC (Fig. 2C).
The GHB-elicited reduction of the corticothalamic EPSC was
antagonized by CGP 56999A (100 nM) in 3 of 3, 10 of 12, and 4 of
4 neurons tested with 250 M, 500 M, and 1 mM GHB, respec-
tively (Fig. 2A). Similar to what had been observed with baclofen,
CGP 56999A produced an increase over the control amplitude in
the presence of GHB (Fig. 2A), and no differences in the effect of
GHB were observed between EPSCs with different kinetics.
These results indicate that the totality of GHB effects on the
corticothalamic EPSCs recorded in TC neurons occurs through
activation of GABAB receptors. In the hippocampus, however, an
effect of GHB on the EPSPs and IPSPs evoked in CA1 neurons
after stimulation of Schaeffer collateral– commissural fibers
could still be observed when GHB was applied in the continuous
presence of the GABAB receptor antagonists CGP 35348 (500
M) (Berton et al., 1999) or CGP 55845 (1M) (Cammalleri et al.,
2002). To match this experimental paradigm, we applied GHB in
the continuous presence of 1 mM CGP 35348, a concentration
that fully antagonizes the response to a maximal concentration of
baclofen (Fig. 2D). Also in this condition, however, GHB was
never capable of inducing a reduction of the corticothalamic
EPSC (n 8) (Fig. 2D).
Figure 1. Effect of ()baclofen on the corticothalamic EPSC. Baclofen (0.1 and 10 M)
reversibly decreases the amplitude of the EPSC by 23% ( A) and 76% ( B), respectively. The
GABAB antagonist CGP56999A (100 nM) antagonizes the effect of baclofen at both concentra-
tions and increases the EPSCs by 12% compared with the control amplitude. Each trace in A and
B is the average of 10 –20 EPSCs. C, Dose–response curve of the effect of baclofen on the
corticothalamic EPSCs.
Figure 2. Effect of GHB on the corticothalamic EPSC. A1, GHB (250M) decreases the am-
plitude of the EPSC by 11%. This effect is antagonized by CGP56999A (100 nM), which also
increases the EPSC size by 16% compared with control. A2, Superimposition of the individual
synaptic currents used to build up the averages presented in A1 (control in black; GHB in gray).
B1, GHB (500M) produces a reversible 22% decrease of the EPSC. B2, Superimposition of the
individual synaptic currents used to build up the averages presented in B1 (control in black; GHB
in gray). C, Recordings from one of the few TC neurons in which GHB fails to decrease the EPSC
amplitude show that 10M baclofen decreases this synaptic current by 90%. Perfusion with the
excitatory amino acid antagonists (CNQX and APV) blocks the electrically evoked corticotha-
lamic EPSC. D, In the continuous presence of the GABAB antagonist CGP35348 (1 mM), GHB (500
M) has no effect on the EPSC. The lack of effect of 10M baclofen on the EPSC after washout of
GHB demonstrates that this concentration of CGP 35348 fully blocks presynaptic GABAB recep-
tors. Each trace in A1, B1, C, and D is the average of 10 –20 EPSCs.
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Effect of GHB on NRT-mediated IPSCs
GHB also decreased the amplitude of NRT-derived GABAA IP-
SCs with a similar potency as against the EPSCs (see below), but
at low concentrations (250 M–1 mM) it was effective on only
41% of the IPSCs. In particular, 250 M GHB did not produce
any effect on 13 of 14 neurons (Fig. 3A), whereas a 14% reduction
was observed in 1 neuron (Fig. 4A,B). Increasing the GHB con-
centration to 500 M induced a 25 8% reduction of the IPSCs
in 21 of 42 neurons (Fig. 3B), whereas 1 mM GHB produced a
29  10% reduction in 9 of 19 neurons (Fig. 4A,B); however,
application of 10 mM GHB induced a 54 10% decrease in every
TC neuron tested (n 7) (Figs. 3C, 4A,B).
The GHB-induced reduction of the NRT-derived IPSCs was
always fully antagonized by CGP 56999A (100 nM) (n 1 and 4,
for 250 and 500 M GHB, respectively) (Fig. 3B). In addition, in
the continuous presence of CGP 56999A (100 nM), application of
GHB (500 M) never decreased the IPSC amplitude (n  10)
(Fig. 3D).
In 10 of the 31 neurons that were insensitive to either 500 M
or 1 mM GHB, we were able to apply baclofen (5–10 M) after
washout of GHB. In each of these 10 neurons, baclofen decreased
the IPSC amplitude by the same amount as in those neurons in
which GHB was active (Fig. 3E).
It has been claimed that some of the actions of GHB observed
in vitro when using high micromolar to low millimolar concen-
trations could be caused by its conversion to GABA via the GHB
dehydrogenase (Hechler et al., 1997). If this were the case under
the experimental conditions used to record IPSCs, one would
have expected to see a change in holding current caused by the
continuous activation of GABAA receptors. No change in holding
current, however, was observed in any experiments on the IPSCs,
nor has any change been reported during similar experiments in
cortex and hippocampus (Jensen and Mody, 2001).
Effects of NCS 382
To completely exclude the involvement of putative GHB recep-
tors in the action of GHB on thalamic synaptic currents, we then
looked at the effect of the putative GHB receptor antagonist NCS
382. We started by investigating the action of this compound
applied alone, because no study has thoroughly addressed this
issue so far.
NCS 382 at a concentration of 50 –100 M, which has been
shown to be effective against GHB action in NCB20 cells (Kem-
mel et al., 1998), had no effect on the EPSC amplitude (n  5)
(Fig. 5A). At concentrations 300 M, however, NCS 382 pro-
duced a reversible increase in the EPSC amplitude. In particular,
at 300M, 500M, and 1 mM, NCS 382 increased the EPSC by 10
and 20% (n  2), 10 and 12% (n  2), and 24  4% (n  6),
respectively (Fig. 5B). Conversely, application of 1 mM NCS 382
decreased the amplitude of ISPCs by 21 5% (n 4) (Fig. 5C).
Despite the narrow range within which NCS 382 alone had no
action on synaptic currents, we then tested the ability of NCS 382
to antagonize the effect of GHB. Application of NCS 382 at 100
M–1 mM had no effect on the GHB-elicited reduction of the
EPSC (Fig. 6A), or it prevented the full block of the GHB re-
sponse by a GABAB receptor antagonist. In addition, at concen-
tration500 M, NCS 382 could elicit an additional decrease to
that produced by GHB (Fig. 6B) (i.e., 20% reduction in one of
three neurons tested with 500 M GHB and 18% in two of seven
neurons tested with 1 mM GHB), as reported previously for the
sensory EPSP in the same thalamic nucleus (Emri et al., 1996b).
Similarly, application of 500 M or 1 mM NCS 382 did not
antagonize the effect of GHB (250 M, n 1; 500 M, n 4) on
the IPSC amplitude (Fig. 6C); however, in three of five neurons
tested with 1 mM NCS 382, it produced an additional 18  7%
decrease in the IPSC amplitude. Overall, therefore, NCS 382
shows a number of nonspecific actions on synaptic currents that
drastically limit its use.
Figure 3. Effect of GHB on the NRT-derived IPSC. A1, GHB (250 M) has no effect on the
amplitude of the GABAA IPSC. A2, Superimposition of the individual synaptic currents used to
build up the averages presented in A1 (control in black; GHB in gray). The IPSCs recorded in
control condition and during GHB application have been offset for clarity. B1, GHB (500 M)
decreases the amplitude of the IPSC by 20%. This effect is antagonized by CGP 56999A (100 nM).
B2, Superimposition of the individual synaptic currents used to build up the averages presented
in B1 (control in black; GHB in gray). C, GHB at 10 mM reversibly decreases the IPSC amplitude by
48%. D1, In the continuous presence of CGP 56999A (100 nM), GHB (500M) has no effect on the
IPSC. D2, Superimposition of the traces shown in D1. E, Recordings from one of the VB TC
neurons in which 500M GHB fails to decrease the IPSC amplitude show that 10M baclofen
reduces this synaptic current by 72%. Each trace in A1, B1, and C–E is the average of 10 –20
IPSCs.
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Lack of effect of NCS 356 and trans-4-hydroxycrotonic acid
Although GHB actions on synaptic currents were fully blocked by
GABAB receptor antagonists, it might be that GHB receptor may
be disclosed using more potent agonists. We therefore tested the
effect of NCS 356 and 4-HCN, two high-affinity ligands of puta-
tive GHB receptors that have been suggested to possess agonist-
like actions (Hechler et al., 1990, 1993). Application of NCS 356
(500 M) failed to produce any change in the amplitude of the
corticothalamic EPSC (n  18) (Fig. 7A) or the NRT-derived
GABAA IPSC (n  8) (Fig. 7B). In the same neurons, however,
subsequent application of either 500 M GHB or 1–10 M ba-
clofen produced the usual reduction in the synaptic current am-
plitude (Fig. 7A,B). 4-HCN (500 M) was also unable to affect
the IPSC (n 3) (Fig. 7C).
Postsynaptic action of GHB
GHB has already been shown to hyperpolarize TC neurons, an
effect that is mediated by activation of postsynaptic GABAB re-
ceptors and insensitive to NCS 382 (Williams et al., 1995). Be-
cause in the continuous presence of GABAB antagonists the un-
masking of a GHB receptor-mediated response on hippocampal
synaptic currents has been reported recently (Berton et al., 1999;
Cammalleri et al., 2002), we wonder whether under similar con-
ditions a postsynaptic effect of GHB on TC neurons could also be
highlighted.
From a holding potential of60 mV, GHB (500 M–10 mM;
n 32) produced an outward current (Fig. 8A,B), with an ED50
of 1.2 mM. In the continuous presence of CGP 56999A, however,
at a concentration (300 nM) that fully blocked the maximal re-
sponse to baclofen (10M) (n 4) (Fig. 8C), GHB was unable to
elicit any outward current (n 12) (Fig. 8B).
Action of GHB on intrathalamic oscillations
Having established the action of GHB on corticothalamic EPSCs,
NRT-evoked IPSCs, and TC neurons, we examined the ability of
this drug to affect intrathalamic oscillations using extracellular
Figure 4. Summary of the effects of GHB on the corticothalamic EPSC and the NRT-derived
GABAA IPSC. A, Percentage of EPSCs and IPSCs affected by different GHB concentrations. Note
that although almost all EPSCs are affected by GHB (0.25–1.0 mM), a much smaller proportion of
IPSCs is sensitive to these concentrations. At 10 mM, all EPSCs and IPSCs are decreased by GHB. B,
Effect of different GHB concentrations on the amplitude of EPSCs and IPSCs. No difference in the
decrease elicited by GHB is observed between EPSCs and those IPSCs that are sensitive to GHB.
Figure 5. Effects of NCS 382 applied alone. A1, NCS 382 (100 M) has no effect on the
corticothalamic EPSCs amplitude. A2, Superimposition of the traces shown in A1. B, NCS 382 (1
mM) produces a reversible 18% increase in the corticothalamic EPSC. C, NCS 382 (1 mM) produces
a reversible 18% decrease in the NRT-derived IPSC. Each trace in A–C is the average of 10 –20
EPSCs or IPSCs.
Figure 6. Effect of NCS 382 on the GHB-induced decrease of EPSCs and IPSCs. A, NCS 382 (1
mM) does not antagonize the GHB-induced decrease of the corticothalamic EPSC, whereas CGP
56999A (100 nM) does. B, Recordings from one of the neurons in which NCS 382 (1 mM) produces
a decrease of the EPSC additional to that evoked by GHB on the EPSC. C, Lack of effect of NCS 382
(1 mM) on the GHB-induced decrease of the IPSC. Each trace in A–C is the average of 10 –20
EPSCs or IPSCs.
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recordings of multiunit activity in the VB. Stimulation of the
cortical afferents, achieved by delivering a brief stimulus to the
internal capsule, elicited slow intrathalamic oscillations of firing
activity (frequency, 1.5 0.4 Hz; n 9 recordings in nine differ-
ent slices) consisting of action potential bursts in few TC neurons
(1.8 0.4 U) with an oscillatory index of 51 7% (Fig. 9A). After
application of 250 M GHB, the oscillatory response to internal
capsule stimulation comprised a larger number of neurons
(4.7  0.5 U; p  0.001) and occurred at a higher frequency
(3.1  1.0 Hz; p  0.01), with an increased oscillatory index
(72 8%; p 0.001) (Fig. 9B–D). Interestingly, in some exper-
iments (n 3), the oscillatory activity recorded in the presence of
GHB became self-sustained, i.e., it no longer required electrical
stimulation of the cortical afferents (data not shown). All of these
effects of GHB were reversed after removal of the drug from the
perfusion medium (frequency, 1.3  0.4 Hz; number of units,
2.2 0.3; oscillatory index, 62 6%) (Fig. 9A–D). Application of
500M GHB, on the other hand, abolished evoked intrathalamic
oscillations in four of five cases (Fig. 9E).
Discussion
The main conclusion of this investigation is that in the concen-
tration range (250 –500 M) that elicits SWDs, GHB instates an
imbalance between the excitatory and inhibitory drives to TC
neurons because it decreases 96% of corticothalamic glutamater-
gic EPSCs but only 43% of the NRT GABAAergic IPSCs. Low
GHB concentrations (250 M) also increase intrathalamic oscil-
lations evoked by cortical stimulation.
In addition, our results demonstrate that these thalamic GHB
effects are mediated by GABAB receptors and strongly question
the use of NCS 382 and NCS 356 and 4-HCN as putative GHB
receptor antagonist and agonists, respectively.
GABAB versus GHB receptors
That all GHB actions in VB are mediated by GABAB receptors is
in agreement with previous in vitro electrophysiological experi-
ments in another thalamic nucleus (Williams et al., 1995; Emri et
al., 1996b) and any brain areas examined so far, i.e., substantia
nigra (Harris et al., 1989), hippocampus (Xie and Smart, 1992b;
King et al., 1997), ventral tegmental area (VTA) (Madden and
Johnson, 1998), and cortex (Jensen and Mody, 2001). Berton et
al. (1999) and Cammalleri et al. (2002), however, reported that in
the presence of CGP 35348 (500 M) or CGP 55845 (1 M),
application of GHB (600 M) decreases EPSPs or GABAA IPSPs,
respectively, in CA1 neurons in vitro, an effect abolished by NCS
382. Using a similar protocol, we did not detect any GHB
receptor-mediated action on thalamic EPSCs and IPSCs. Al-
though this discrepancy may reflect a real difference between
thalamus and hippocampus, it is likely that GHB was still acting
on presynaptic GABAB receptors in these two hippocampal stud-
ies, because 1 mM is necessary to fully block presynaptic GABAB
receptors in this area (Davies et al., 1991). Indeed, Berton et al.
(1999) and Cammalleri et al. (2002) did not test whether presyn-
aptic GABAB receptors were fully blocked. Furthermore, al-
though these studies reported no effect of 500M NCS 382 alone,
an increase (11 and 65% at 100 M and 2 mM, respectively) has
been observed in hippocampal field potentials (King et al., 1997),
Figure 7. Lack of effect of NCS356 and 4-HCN on EPSCs and IPSCs. A, NCS356 (500M) has no
effect on the EPSC, whereas the decrease induced by baclofen (1M) indicates that the synaptic
current in this neuron is sensitive to GABAB receptor activation. B, NCS356 (500 M) fails to
affect the NRT-derived IPSC, whereas the decrease induced by baclofen (10M) indicates that
the synaptic current in this neuron is sensitive to GABAB receptor activation. C1, 4-HCN (500M)
has no effect on the GABAA IPSC amplitude. C2, Superimposition of the traces shown in C1. Each
trace in A–C is the average of 10 –20 EPSCs or IPSCs.
Figure 8. GHB-elicited outward current. A, Application of GHB dose-dependently activates
an outward current in a VB TC neuron (A1). A2 shows the dose–response curve of the effect of
GHB in one neuron. Numbers in the plot refer to the order of application, as indicated in A1. For
comparison, the inset shows the outward current activated in the same neuron by 10 M
baclofen. B, The outward current elicited by 1 mM GHB is fully antagonized by CGP 56999A (300
nM). C, The outward current elicited by 10M baclofen is fully antagonized by CGP 56999A (300
nM).
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and our analysis has highlighted nonspecific NCS 382 effects in
thalamus.
Physiologically relevant GHB receptors?
Two critical issues still confound our understanding of brain
GHB effects. It has been suggested that submicromolar to low
micromolar GHB concentrations are needed to evoke GHB re-
sponses mediated by putative GHB receptors; however, the only
in vitro studies that reported electrophysi-
ological effects of GHB concentrations
100 M (Crunelli and Leresche, 2002b)
are in cell lines (Kemmel et al., 1998; Kem-
mel et al., 2003). In all other in vitro stud-
ies, including those in areas with high
GHB binding sites (e.g., VTA, cortex, hip-
pocampus, thalamus), a threshold GHB
concentration of 100 –300 M was re-
quired to observe GHB effects (Harris et
al., 1989; Xie and Smart, 1992a; Williams
et al., 1995; Emri et al., 1996b; Madden and
Johnson, 1998), and these responses were
then invariably abolished by GABAB an-
tagonists. With regard to in vivo investiga-
tions, most of the studies using systemic or
iontophoretic applications of GHB (Diana
et al., 1991; Engberg and Nissbrandt, 1993;
Godbout et al., 1995; Aizawa et al., 1997)
cannot help to clarify this issue because the
brain GHB concentration was not mea-
sured. On the other hand, the expression
of SWDs (i.e., the only behavioral effect of
systemically injected GHB for which the
brain GHB concentration–response curve
is available) requires a threshold brain
GHB concentration of 240 M (Snead,
1991), and here we have indeed shown that
250 M GHB fully acts on GABAB recep-
tors (Williams et al., 1995; Emri et al.,
1996b).
Furthermore, it has been claimed that
the block by systemic NCS 382 of the be-
havioral and in vivo electrophysiological
effects of GHB supports the existence of
GHB receptors (Maitre, 1997). We would
argue, however, that because the brain
NCS 382 concentration after systemic ad-
ministration has never been measured,
any apparent block of GHB effects by NCS
382 in vivo should be treated with caution,
because it may result from any of its non-
specific actions in thalamus (Emri et al.,
1996b; this study) and hippocampus (King
et al., 1997), as well as in the cerebellum,
which has no GHB binding sites (Bernas-
coni et al., 2002). This negative view of the
existence of physiologically relevant brain
GHB receptors is also supported by the
lack of action on thalamic EPSCs and IP-
SCs of NCS 356 and 4-HCN (this study),
two high-affinity GHB receptor ligands–
agonists in cell lines (Kemmel et al., 2003)
and in biochemical tests (Hechler et al.,
1990, 1993), and by the inability of 4-HCN
to elicit SWDs in vivo (Depaulis et al., 1988).
Thalamic GABAB receptor subtypes
The existence of GABAB receptor subtypes (Bonanno and Raiteri,
1993; Guyon and Leresche, 1995) and of a presynaptic GHB–
GABAB receptor complex (Banerjee and Snead, 1995) has been
proposed, although no support from cloning studies is available
yet. Interestingly, GABABR1a/b and GABABR2 immunoreactiv-
Figure 9. Effect of GHB on population activity in the VB. A, In control conditions, the response to stimulation of the cortical
afferents recorded in the VB shows a period of transient multiunit bursting with a dominant frequency of 1.8 Hz (see autocorel-
logram on the right; bin width 20 msec). After application of 250 M GHB, the response comprises activity from an increased
number of neurons, leading to an increase in the total spike count, and occurs at a higher frequency (2.2 Hz) (see autocorrelogram
on the right). After washout of GHB, the response is again characterized by fewer bursting neurons and occurs at a lower frequency
(1.7 Hz). All autocorrelograms were normalized to the peak value obtained in control conditions. The dotted lines in the autocor-
relogram indicate the 99% confidence limit. B–D, Summary (from 9 multiunit recordings in 9 different slices) of the effect of 250
M GHB on the oscillation frequency ( B), the oscillatory index (see Materials and Methods) ( C), and the number of units compris-
ing the oscillatory response ( D) (*p 0.01; **p 0.001). E, After a brief stimulus delivered to the internal capsule, an extracel-
lular recording in the VB displays transient neuronal activity consisting of action potential bursts in a small number of TC neurons
(see enlarged section). This response is reversibly abolished by application of 500M GHB.
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ity was detected only on postsynaptic elements in the VB (i.e., on
TC neurons) (Kulik et al., 2002). The lack of GABAB immunore-
activity in VB presynaptic elements is surprising when compared
with this and previous electrophysiological studies and has been
explained by the existence of yet unidentified GABAB clones (Ku-
lik et al., 2002). In this respect, our findings that60% of GABAA
IPSCs in VB are unaffected by low GHB concentrations but show
a normal sensitivity to baclofen would suggest the existence of
thalamic GABAB autoreceptor subtype(s) with a low sensitivity to
GHB. Interestingly, the threshold concentration for GABAB-
mediated effects of GHB in cortex and hippocampus (Jensen and
Mody, 2001) is 10-fold higher than in thalamus.
Mechanism of GHB-elicited SWDs and decreased states
of vigilance
A preferential effect of GHB on basal glutamate versus GABA
release in vivo was shown in VB (Banerjee and Snead, 1995) but
not in cortex (Hu et al., 2000), although the significance of
changes in basal thalamic release for the EEG expression of a
paroxysmal activity is unclear. Electrophysiologically, low (250
M–1 mM) GHB concentrations hyperpolarize TC neurons (Wil-
liams et al., 1995) and decrease with a similar potency sensory
EPSPs (Emri et al., 1996b), corticothalamic EPSCs, and 40% of
GABAA IPSCs in VB, whereas the remaining IPSCs are unaffected
(this study). On the basis of these results, and because SWDs can
be elicited by direct injection of GHB into the VB (Snead, 1991),
we suggest that a substantial component of the mechanism un-
derlying the generation of SWDs by systemic GHB is caused by an
imbalance of the physiological excitatory and inhibitory drives to
TC neurons in favor of an increased inhibition. This would not
only tend to slightly hyperpolarize TC neurons and decrease their
afferent corticothalamic and sensory excitatory volleys, but
would also leave the TC neuron population with a substantial
proportion of unaltered NRT phasic inhibition, thus helping to
impose that periodic inhibition that sculptures the electrical be-
havior of TC neuron during this paroxysmal activity (Steriade
and Contreras, 1995; Pinault et al., 1998; Huntsman et al., 1999;
Blumenfeld and McCormick, 2000; Tancredi et al., 2000;
D’Arcangelo et al., 2002; Slaght et al., 2002). The ability of low
(250 M) GHB concentrations to increase absence-like intratha-
lamic oscillations clearly supports this view. It should be pointed
out, however, that in addition to directly activating corticotha-
lamic excitatory synapses, internal capsule stimulation will also
strongly excite NRT neurons by activating both corticothalamic
and thalamocortical fibers. Furthermore, because the NRT plays
a key role in the maintenance and initiation of intrathalamic
oscillations, the involvement of specific GHB-mediated effects in
this nucleus should not be discounted when attempting to under-
stand the pro-rhythmic actions of this drug. Whether an imbal-
ance of excitatory and inhibitory drives might account for other
GHB actions also remains to be elucidated, although it is worth
noting that in VTA a differential control of EPSCs and IPSCs was
recently suggested to underlie the rewarding properties of nico-
tine (Mansvelder et al., 2002).
Another critical feature of the GHB model of absence seizures
that can also be explained by our results is the finding that SWDs
are evoked within a narrow range of GHB concentrations (240 –
500 M in the rat), because higher concentrations lead to a pro-
gressive slowing of the EEG associated with increasingly strong
sedation and sleep promotion (Snead et al., 1976; Snead, 1991).
Our results show that at a GHB concentration of 250 M, the
imbalance between the excitatory and inhibitory drives to TC
neurons is already present and that slow intrathalamic oscilla-
tions are increased. At 500M, although the preferential effect on
EPSCs versus IPSCs remains, the oscillations are partly abolished,
probably because the (postsynaptic) activation of G-protein
gated inward rectifying K current (GIRK) is stronger. At even
higher concentrations, the dampening of both excitatory and in-
hibitory inputs, together with the increasing GIRK activation,
would result in a stronger hyperpolarization of TC neurons, nec-
essary to express those intrinsic–network activities associated
with states of progressively decreasing vigilance (Steriade, 2000;
Hughes et al., 2002). This thalamic action, together with similar
effects on cortical neurons (Godbout et al., 1995; Jensen and
Mody, 2001), might well account for the sedation and normal-
ization of sleep patterns, which are exploited in the illicit use of
GHB and its clinical use in narcolepsy, respectively.
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